MTS004

Main study objectives The main objective of this study is to evaluate the pharmacokinetic (PK) characteristics of MTS004 orodisintegrating tablets (test formulation) (swallowed directly without water or with water) and dextromethorphan hydrobromide and quinidine sulfate capsules (reference formulation, trade name: NUEDEXTA®) in healthy adult subjects under fasting conditions, and to calculate the relative bioavailability of dextromethorphan hydrobromide (DM, 20 mg) and quinidine sulfate (Q, 10 mg) of the test formulation compared with the reference formulation when swallowed directly without water or with water. Secondary study objectives The secondary objective of this study is to evaluate the safety of the test formulation after a single dose in healthy adult subjects under fasting conditions.